Shailendra Giri, PhD
S-nitrosylation mediated inactiviation of TSG in ovarian cancer
Chronic inflammation has become a well-accepted risk factor for epithelial-derived malignancies, including ovarian cancer. But how inflammation contributes to the process of carcinogenesis is a grey area. If successful, Dr. Giri's study will elucidate the possible novel regulation of chemical inactivation of LKB1-AMPK pathway by inflammatory mediators in ovarian cancer and lead to a better understanding of the inflammation mediated mechanisms and open up new therapeutic approaches to control inflammation which is an under investigated area of ovarian cancer.
2009 Gilman Family Scholar
Amelie Margarete Lutz, MD, PhD
Early Detection of Ovarian Cancer Using Targeted Microbubble-Enhanced Ultrasound
The primary objective of Dr. Lutz's proposal is to validate and refine molecularly targeted microbubble contrast enhanced ultrasound (CEUS) for non-invasive, in-vivo imaging of the ovarian cancer-related angiogenesis. Like other solid tumors, ovarian cancer is critically dependent on functional vascular supply for tumor growth and metastasis. Angiogenesis, the recruitment of new blood vessels, occurs at a very early stage in ovarian cancer development. This work addresses an ovarian-specific target associated with angiogenesis. The translational goal is to apply the approach as part of a multi-modal ovarian cancer screening strategy.
Elda Righi, MD
DFCI/Harvard Cancer Center, Massachusettes General Hospital (East)
Blockade of the CXCL12 and VEGF axes in ovarian cancer
One of the reasons ovarian cancer progresses with few evident symptoms may be the combination of ways in which the cancer escapes the patient's immune system and organizes a vascular supply to serve its own needs. CXCL12 and VEGF are two factors made in excess by human ovarian cancer and they appear to work together to increase each others effects adding to the ways in which the tumor escapes from control. Dr. Righi, through excellent collaborators to mouse models, proposes to test the idea that blockade of both CXCL12 and VEGF would be significantly better than blocking either one. If successful, this work would add a new dimension to therapy for ovarian cancer patients.